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ABSTRACT
Background: The increasing sub-classification of cancer patients due to more detailed molecular classi-
fication of tumors, and limitations of current trial designs, require innovative research designs. We pre-
sent the design, governance and current standing of three comprehensive nationwide cohorts
including pancreatic, esophageal/gastric, and colorectal cancer patients (NCT02070146).
Multidisciplinary collection of clinical data, tumor tissue, blood samples, and patient-reported outcome
(PRO) measures with a nationwide coverage, provides the infrastructure for future and novel trial
designs and facilitates research to improve outcomes of gastrointestinal cancer patients.
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Material and methods: All patients aged 18 years with pancreatic, esophageal/gastric or colorectal
cancer are eligible. Patients provide informed consent for: (1) reuse of clinical data; (2) biobanking of
primary tumor tissue; (3) collection of blood samples; (4) to be informed about relevant newly identi-
fied genomic aberrations; (5) collection of longitudinal PROs; and (6) to receive information on new
interventional studies and possible participation in cohort multiple randomized controlled trials
(cmRCT) in the future.
Results: In 2015, clinical data of 21,758 newly diagnosed patients were collected in the Netherlands
Cancer Registry. Additional clinical data on the surgical procedures were registered in surgical audits
for 13,845 patients. Within the first two years, tumor tissue and blood samples were obtained from
1507 patients; during this period, 1180 patients were included in the PRO registry. Response rate for
PROs was 90%. The consent rate to receive information on new interventional studies and possible
participation in cmRCTs in the future was >85%. The number of hospitals participating in the cohorts
is steadily increasing.
Conclusion: A comprehensive nationwide multidisciplinary gastrointestinal cancer cohort is feasible
and surpasses the limitations of classical study designs. With this initiative, novel and innovative studies
can be performed in an efficient, safe, and comprehensive setting.
Background
Patients with gastrointestinal cancer are traditionally treated
according to several clinical and histopathological character-
istics (e.g., tumor location, TNM stage, tumor grade).
However, patients with similar traditional features, under-
going similar treatment, may show important differences in
clinical outcome [1–3]. The underlying biological differences
result in an increasing number of disease sub-classifications,
based on efforts towards more individualized (or tailored)
patient treatment.
However, due to the increasing sub-classifications of
patients, there is a need for novel clinical trial designs and
methods for data acquisition and patient recruitment. Current
clinical trials have important limitations. First, recruitment is
extremely restricted: only 5–10% of all patients are enrolled in
a clinical trial [4]. Second, clinical trials include only highly
selected patient populations, which leads to low inclusion
rates and further limits their external validity. Third, data col-
lection may be inadequate, due to insufficient follow-up or
the absence of patient-reported outcomes (PROs); this, in
turn, results in high costs or premature termination of the
study. Finally, clinical trials are often underpowered for post-
hoc subgroup analyses [4, 5]. Consequently, the current clin-
ical trial system has been described as ‘broken’, ‘in crisis’, and
‘not fit for purpose’ [6]. However, there is a paucity of data on
a population level. Current nationwide data initiatives such as
the Surveillance, Epidemiology, and End Results (SEER) and
the Medicare database, contain selected populations and do
not include biobanking or data on quality of life [7].
In an effort to address these issues, three comprehensive
nationwide cohorts of pancreatic, esophageal/gastric, and
colorectal cancer patients were started in the Netherlands
(the Dutch PAncreatic CAncer Project ‘PACAP’; the
Prospective Observational Cohort study of Oesophageal-gas-
tric cancer Patients ‘POCOP’; and the Prospective Dutch
ColoRectal Cancer cohort ‘PLCRC’).
Collaborating as the 3P initiative, these three cohorts col-
lect clinical data, tumor tissue, blood samples, and PROs of
gastrointestinal cancer patients. The goal is to facilitate
research by (inter)national research groups to improve the
survival and quality of life of patients with one of these three
cancers. The protocol of PLCRC (describing the practical pro-
cedures and considerations of the cohort) was previously
published [8].
We present the design, proceedings, governance, opportu-
nities, and pitfalls of the three collaborating comprehensive
prospective nationwide gastrointestinal cancer cohorts.
Material and methods
Inclusion and informed consent
All patients aged18 years with pancreatic, esophageal/gas-
tric, or colorectal cancer are eligible. Excluded from participa-
tion are patients with mental incompetence or insufficient
understanding of the Dutch language to provide informed
consent. Patients are asked to sign a multi-source informed
consent including the following components: (1) reuse of
clinical data from all medical files; (2) tissue sampling; (3)
blood sampling; (4) to be informed about relevant newly
identified genomic aberrations; (5) PROs; and (6) receiving
information on new interventional studies and possible par-
ticipation in cohort multiple randomized controlled trials
(cmRCT) in the future. Patients can provide written informed
consent for each component separately, and may alter or
retract consent for each component at any point in time.
As clinical data are crucial to the cohorts for obvious reasons,
patients that do not give informed consent for this part of
the study are considered ineligible.
Patients who want to consent to receiving information on
new interventional studies in the future are informed in
detail about the cmRCT design. They are informed: (i) that
their data may be (re)used for the evaluation of new inter-
ventions offered to patients within the cohort; (ii) that they
may in future be randomly selected for an experimental
intervention, which they may accept or refuse at a later
stage; and (iii) that when enrolled in the cmRCT, they cannot
participate in other studies investigating the same interven-
tion or outcome. This procedure is identical to current prac-
tice for classical RCTs. However, patients participating in one
of the 3P cohorts, but who are not enrolled in a cmRCT, may
participate in other studies (e.g., classical RCTs) outside of the
cohorts.
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Clinical data
Clinical data are obtained from the Netherlands Cancer
Registry (NCR), hosted by the Netherlands Comprehensive
Cancer Organization. The NCR contains clinical data from
all relevant medical charts registered by trained data man-
agers for every patient diagnosed with cancer in the
Netherlands [9]. In 2015, the item set of the NCR was
renewed and expanded to meet the requirements of the
gastrointestinal cancer cohorts and to facilitate research.
Items focus on patient, tumor and treatment characteris-
tics, adverse events, and survival. Importantly, medical files
are revisited multiple times to ensure the registration of
clinical items from diagnosis until death. For every new
cancer patient, 200–400 clinical data items are stored in
an online secured database using Snowmed ontologies. A
collaboration between the national tumor working groups,
research groups, and the NCR has resulted in data sharing
initiatives allowing data from the NCR to be merged with
other databases, e.g., for surgical audits. In these audits,
oncologic surgeons collect data for a nationwide auditing
initiative, supervised by the Dutch Institute for Clinical
Auditing (DICA) [10]. Participation in these audits is man-
datory for each hospital. For each surgical patient, an add-
itional set of 100–150 surgical clinical data items is
collected.
Importantly, according to Dutch law, collection of clinical
data in the NCR and surgical audits does not require
informed consent; patients sign informed consent for reuse
of these data (as described above).
Tissue and blood samples
For POCOP and PACAP, tissue and blood sampling is organ-
ized in close collaboration with the Parelsnoer Institute, an
existing national initiative facilitating biobanking for 17 differ-
ent diseases, including esophageal/gastric and pancreatic
cancer [11,12]. Fresh frozen tumor and normal tissue samples
are taken from the surgical resection specimen of the pri-
mary tumor. Blood samples are withdrawn before and after
surgery.
For colorectal cancer, the Parelsnoer Institute facilitates
biobanking for hereditary cases. Therefore, patients enrolling
in PLCRC cohort can consent to tumor and tissue collection
and biobanking separately, in order to collect biomaterial of
all cases of colorectal cancer [8]. Both fresh frozen and forma-
lin-fixed paraffin embedded tumor and normal tissue samples
are obtained from the surgical resection specimen of the pri-
mary tumor. Furthermore, blood samples may be collected as
needed for specific study protocols. In PLCRC, the informed
consent allows for the withdrawal of blood samples for
future research questions without precisely specifying the
time point of withdrawal, the patient population studied,
and/or the specific tests that will be performed. There is a
limit of 10 tubes per patient per year, collected only at the
time of regular blood withdrawals. Details of the biobanking
standard operating protocols are available in the
Supplementary Materials.
Patient-reported outcomes
PROs, including health-related quality of life (HRQoL), are
increasingly important outcomes for patients and physicians,
and are also of growing interest to other healthcare partners.
The PROs that are administered longitudinally were selected
in close collaboration with national experts, international
advisors, patients, and patient advocates. A core set of vali-
dated questionnaires is used to measure generic and disease-
specific HRQoL (e.g., the EuroQol and European Organization
for Research and Treatment of Cancer (EORTC) question-
naires) [13,14]. In addition, a cohort-specific set of question-
naires is used to measure, e.g., self-reported adverse events
and work productivity. The composition of questionnaires is
flexible and may be altered depending on the inclusion of
new studies.
To increase patient participation and response rates,
patients may complete questionnaires on paper, or online
(computer, tablet or smartphone). Questionnaires are pro-
vided by the digital tracking system Patient-Reported
Outcomes Following Initial treatment and Long-term
Evaluation of Survivorship (PROFILES), a noncommercial initia-
tive with an online patient management system used to
send online or paper PROs and automatic reminders [15].
Data access and integration
As mentioned, the main goal of the 3P initiative is to facili-
tate (inter)national research by collecting and sharing high-
quality data. Every researcher (national and international) can
use the data and biomaterial gathered to improve the out-
come for patients with pancreatic, esophageal/gastric, and
colorectal cancer. To ensure a sustainable and secure use of
the data, a procedure to evaluate requests to access the data
is in place (see: ‘Governance’ below). Furthermore, participat-
ing centers may at any time request data of patients enrolled
at their own center. Besides the evaluation of the request, a
generic and easy-to-use information technology (IT) infra-
structure to facilitate the actual use of data is essential. The
IT backbone of the three cohorts is based on the FAIR
(Findable, Accessible, Interoperable, and Reusable) principles
[16] and has been created in close collaboration with
national and international research initiatives, such as the
Dutch national node of the Biobanking and BioMolecular
resources Research Infrastructure (BBMRI), Dutch Translational
Research IT (TraIT), and the AACR (American Association for
Cancer Research) project ‘Genomics, Evidence, Neoplasia,
Information, Exchange’ (GENIE). As mentioned, the different
data types are gathered through existing best practices (e.g.,
NCR, PROFILES). These data are combined using an IT solu-
tion in which the data types are matched through a unique
study registration (USR) number which is assigned to each
patient at enrollment. A separate enrollment log, only con-
taining USR numbers with corresponding patient identifiers
(name, date of birth, gender and date of inclusion), is stored
on a different secured server to secure patients’ identity.
Data from the different sources are regularly added using
data dumps. In the future, the databases can and will be
enriched with data from other studies. Eventually all clinical,
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biological, and PROs data are integrated and made accessible
in a secure way. This allows (among other tasks) to scrutinize
the data for selection bias of the informed consent compo-
nents, and attrition or responder bias in patients that did
respond compared with those who did not respond to the
PROs.
Statistical analysis
Data were analyzed using IBM SPSS statistics version 21 (IBM,
Armonk, NY, USA). Frequency tables were provided, and cat-
egorical data were presented as frequencies with percen-
tages. No comparative analyses were performed.
Prospective studies
The 3P initiative provides the infrastructure for efficient, safe
and comprehensive clinical evaluation of new interventions
for patients with pancreatic, esophageal/gastric, and colorec-
tal cancer based on classical observational and interventional
clinical study designs, or on the cmRCT design (Figure 1)
[17]. Studies based on the latter design can be performed
because clinical data are collected for all patients enrolled in
the cohorts, including patients who will be randomized to
the standard of care arm and do not need to be approached
for informed consent at the time of a new cmRCT study.
Both cmRCT and multiple simultaneous prospective obser-
vational studies can be performed within the cohorts, as
many variables and endpoints are collected in a standardized
way. If required, the composition of clinical data and PROs
can be altered to accommodate prospective studies.
Additionally, data from the cohorts may be used for studies
performed outside the 3P initiative.
Because clinical data are collected for all patients enrolled
in the cohorts, the cohorts are well suited to serve as the
basis for cmRCTs [17]. To enable cmRCT studies within the
cohorts, patients are not only asked for informed consent for
Figure 1. Flowchart of the cohort multiple randomized clinical trial (cmRCT) design. At enrollment in one of the three cohorts, patients can consent to be selected
and randomized according to the cmRCT design. When a patient is eligible to enter a cmRCT trial, the patient is randomized. When a patient is randomized to the
standard of care arm, no additional steps are undertaken. When a patient is randomized to the intervention arm, the patient is approached and offered the inter-
vention, and signs an additional informed consent when participating in the trial.
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data collection and to be approached for future clinical trials,
but are also specifically asked for future randomization
according to the cmRCT design. To use the database for
cmRCT to evaluate a new intervention, eligible patients
within the cohort can be identified. A randomly selected sub-
group will be offered the experimental intervention. The out-
comes of these patients are compared to the routinely
collected outcomes of eligible patients who were not ran-
domly selected to receive the intervention (i.e., the control
group). Patients not receiving the intervention will not be
informed that they are serving as controls, as is explained at
initial enrollment in the cohort. The intervention is described
in a separate protocol that requires approval of the institu-
tional review board. To avoid overlap with other studies,
each center can decide if it wants to participate in a specific
cmRCT. Patients who accept the intervention have to sign a
separate informed consent.
Governance
In order to obtain data, (inter)national researchers can file a
study proposal using a pre-specified format which will be
assessed by the appropriate tumor-specific scientific commit-
tee (www.dpcg.nl, www.ducg.nl, and www.plcrc.nl).
Submitted research proposals are then reviewed to deter-
mine feasibility and quality, and to ascertain possible dupli-
cate studies. For POCOP and PACAP, study proposals that are
approved by the scientific committee are subsequently pre-
sented to the Dutch Upper GI Cancer Group and the Dutch
Pancreatic Cancer Group, respectively. Participating centers
requesting data of patients enrolled at their own center can
obtain data without following this procedure.
The scientific committees meet 3–4 times a year and are
composed of a multidisciplinary team (including basic scien-
tists, social scientists, clinicians, and patient advocates), repre-
sentatives from all participating centers, and representatives
of the boards of the respective research groups. The scientific
committees control the release of clinical data, PROs, and
blood or tissue samples, to various healthcare partners such
as government and industry (Supplementary Figure S1).
Funding
Financial support of the 3P initiative is based on ad hoc
funding and structural funding. Ad hoc funding consists of
public funds (e.g., the Dutch Cancer Society; The Netherlands
Organization for Health Research, and Development) and
public–private partnerships with pharmaceutical companies.
These partnerships are increasingly popular to create the crit-
ical mass of partners in specific areas and allow to combine
resources, expertise and complementary skills to advance the
understanding of the factors underlying differences in the
clinical outcome. Furthermore, these collaborations allow to
develop drugs at a (possibly) lower cost and faster rate, and
to evaluate the cost-effectiveness of new and costly medica-
tion [18]. Besides the financial support, the 3P initiative is
also supported through data and knowledge-sharing, and
access to information technology (IT) tools.
Ethical considerations and privacy
Studies on the three cohorts are conducted in accordance
with the principles of the Declaration of Helsinki [64th WMA
(World Medical Association) General Assembly, Fortaleza,
Brazil, October 2013] and in accordance with the Dutch
Medical Research Involving Human Subjects Act.
Results
In 2015, clinical data of all newly diagnosed patients with
gastrointestinal cancer were collected within the NCR
including 2284 pancreatic, 3925 esophageal/gastric, and
15,549 colorectal cancer patients. Additional clinical data
regarding the surgical procedure (registered in the surgical
audit) were available for patients who underwent surgery:
881 (39%) pancreatic, 1244 (32%) esophageal/gastric, and
11,720 (76%) colorectal cancer patients. Extensive data on
clinical characteristics and data completeness are reported
elsewhere [8, 19].
In an increasing number of participating hospitals,
the informed consent procedure for PACAP, POCOP, and/or
PLCRC has been implemented (n¼ 22, n¼ 16, and n¼ 12
centers, respectively, as at 1 December 2016). At time of
manuscript acceptance, informed consent to collect tumor
tissue and blood samples was obtained from 538 pancreatic,
199 esophageal/gastric, and 1313 colorectal cancer patients.
During this period, 309 pancreatic, 416 esophageal/gastric,
and 1145 colorectal cancer patients were included in the
PRO registry. Analysis showed that>90% of the patients who
were informed, provided informed consent for one or more
Table 1. Number of patients in the Netherlands Cancer Registry, surgical audits, patient-reported outcomes registries, and biobanking.
PACAP Pancreas POCOP Esophageal/gastric PLCRC Colorectal Total
Netherlands Cancer Registrya 2284 3925 15,549 21,758
Surgical Audita,b 881 1244 11,720 13,845
Biobank 538 199 1313 2050
PROs (eligible) 309 (506) 416 (675) 1145 (1575) 2580 (2756)
PROs response rate, t¼ 0 month 98% 95% 79%c 91%
PROs response rate, t¼ 3 months 63% 73% 63%c 64%
Informed consent was obtained from all patients in the patient-reported outcomes registry and biobanking, as collection of clinical data
does not require informed consent.
a2015 only.
bNumber of registered resections.
cDate of inclusion until 31 August 2016.
PROs: patient-reported outcomes; PACAP: Dutch PAncreatic CAncer Project; POCOP: Prospective Observational Cohort study of esophageal-
gastric cancer Patients; PLCRC: Prospective Dutch ColoRectal Cancer cohort; N/A: not applicable.
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components. Of all patients that consented to receiving
questionnaires, at baseline the response rate was 91%,
whereas this decreased to 64% after 3 months and to 31%
after 6 months.
Table 1 and Figure 2 provide overviews of patients in the
clinical data collection, the PROs, and the biobanking initia-
tives per tumor type. The decrease in response rate over
time is partly because some patients died or dropped out
between the two time points, or had not yet reached the
3-month or 6-month time point. Of all patients who com-
pleted at least one questionnaire, 54% completed the ques-
tionnaires online. In the first 67 PACAP patients, the median
completion time was 40 (IQR 30, range 15–350) min, which
was acceptable to most (70%) of the patients. Over 80% of
patients were satisfied with the questionnaire and would par-
ticipate in the cohort on a regular basis. In addition, most
patients (80%) felt that physicians should pay more attention
to HRQoL.
Consent to receive information about intervention studies
and to participate in cmRCT studies in the future were pro-
vided by 94% of PACAP, 84% of POCOP, and by 85% of
PLCRC patients.
Discussion
The 3P initiative provides a comprehensive, nationwide,
multidisciplinary research infrastructure that accommodates
studies on a national level, providing population-based data.
Extensive and accurate clinical data, tissue samples, blood
samples, and PROs are collected from diagnosis until the
death of patients with pancreatic, esophageal/gastric, and
colorectal cancer after a broad-based informed consent has
been given. The participation rate for each informed consent
item was >80%, including consent to be informed about
interventional studies and to participate in cmRCT studies in
the future. The cohorts overcome many limitations of clas-
sical study designs and allow the performance of multiple
concurrent studies. The collaborative nature of the 3P initia-
tive combined with involvement of all relevant disciplines
and mandated representatives of professional associations
ensures a broad nationwide support.
Although many other clinical registries and biobank initia-
tives are available, only a few initiatives manage to combine
both. The 3P initiative not only contains detailed longitudinal
clinical data and biomaterial of patients, the PROs are col-
lected and patients can easily be approached for future clin-
ical trials. Based on collaboration with the NCR, which
contains clinical data of all Dutch patients diagnosed with
(pancreatic, esophageal/gastric, and colorectal) cancer, a
nationwide coverage is ensured. Completeness of the NCR is
reported to be at least 95% [20]. For comparison: although
the SEER program in the USA has greater absolute numbers,
coverage is only 28% of the total US population [7].
Regarding the Nordic cancer registries (Denmark, Finland,
Iceland, Norway, Sweden, and Faroe Islands), their national
coverage is comparable to the NCR and is reported to be
close to 100% [21]. Recognizing the importance of PROs,
Sweden has also started to collect PROs prospectively over
time and organized by tumor type [22].
In the Netherlands, considerable experience has been
obtained with surgical auditing, leading to case ascertain-
ments of 95%, data completeness of almost 100%, and data
accuracy of 95–99% [10]. The main equivalent for these
audits is the American College of Surgeons National Surgical
Quality Improvement Program (ACS NSQIP) [23]; although
the reported completeness and accuracy is lower compared
to the Dutch audits [24], the absence of universal definitions
or scoring systems hampers proper comparison. Therefore, a
generic and easy-to-use IT infrastructure based on the FAIR
(Findable, Accessible, Interoperable, and Reusable) principles
is essential, but not easy to achieve [16]. Until now, many
Figure 2. Number of signed informed consents obtained, for the collection of biomaterials and PROMs in patients with colorectal-, esophageal/gastric, and pancre-
atic cancer. The number of signed informed consents obtained for collection of biomaterials in patients with esophageal/gastric cancer was not available per cuar-
ter, and is therefore depicted as a total only.
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integration/sharing initiatives in (translational) research have
failed to achieve full potential. This may be due to either
focusing on technology push without sufficient user buy-in
and content, or on supplying only technical solutions for one
individual dataset thereby creating information silos instead
of accessible data. The Handbook for Adequate Natural Data
Stewardship (HANDS) published by the Netherlands
Federation of University Medical Centers, illustrates the active
attitude to break down these information silos and converge
the current (inter)national ongoing efforts [25].
Continuously evolving ethical and legal changes lead to
more stringent criteria, lengthier protocols/patient informa-
tion leaflets, and more informed consents for the use and
even (retrospective) reuse of patient data and biomaterials.
Between 1987 and 2007, the length of the informed consent
documents has doubled, mostly due to formal components
that aim to inform patients as fully as possible [26]. However,
patients who receive brief/simple documents remember the
information provided better than those who receive detailed/
lengthy information [27]. To maximize information retention
of the informed consent procedure of the 3P initiative, infor-
mation is provided through multiple sources including: the
treating physician, a research nurse or physician assistant,
study websites, an online patient movie, brochures, and small
executive summary folders. Cervo et al. studied a similar mul-
tisource informed consent procedure and showed that these
patients retain much more information (95% of the ques-
tions about the informed consent answered correctly) [28]
compared to 56-88% without the provision of multisource
information [27].
In the Netherlands, the cmRCT design complies with the
laws on human medical research and is becoming increas-
ingly accepted in clinical practice. Nevertheless, the design
and the possible future impact on patients have provoked
resistance in other countries. Patients consenting to random-
ization following the cmRCT design, may be included in an
intervention study in the future [17]. Patients who consent to
be approached for future investigations and are later
selected for an cmRCT intervention arm, will receive add-
itional detailed information and will be asked to sign a separ-
ate informed consent for the intervention. Patients in the
control group previously consented at baseline and are fully
aware that, when selected for the control group, they will
not be informed about that particular cmRCT. Although it
remains debatable whether it is ethical not to offer the inter-
vention to these (control) patients, this is no different from a
classical RCT. A progressive, practice-changing agreement in
the PLCRC cohort is that a maximum of 10 tubes per year
may be withdrawn at regular blood withdrawals without the
need to amend the study protocol to specify the timing,
type of tube, and processing steps. This avoids multiple
informed consents, while the assessment of study proposals
from researchers or research groups by the tumor-specific
scientific committees ensures scientific and ethical integrity.
Although the 3P initiative has a nationwide coverage,
intrinsic features of the study population (e.g., the distribu-
tion of age/gender/race, and what is considered the
‘standard of care’ in the Netherlands) may limit external inter-
national validity. However, the large number of included
patients allows the selection of sufficiently large subgroups.
Also, the standardized collection of data and biomaterials
using international guidelines allows researchers to integrate
data from multiple population-based registries, and to ana-
lyze differences in the standard of practice and subsequent
clinical outcome.
A second limitation is that the clinical data in the NCR are
only as accurate as the information provided in the relevant
medical files. Therefore, synoptic and standardized reporting
initiatives are ongoing [29]. A third limitation (or challenge) is
the current dependency on ad hoc funding. This may result
in additional costs for researchers if funding is insufficient to
maintain the initiative, which might raise the threshold for
researchers to make use of the cohorts. However, since the
data and biomaterials are shared with multiple researchers,
the financial contribution per research protocol will (if intro-
duced) be lower than the costs for conducting each protocol
separately. Importantly, retrospective observational studies
using the available data can be performed without making a
financial contribution. Nevertheless, structural financial sup-
port is preferable to ad hoc funding, which has been (in
part) realized through public–private partnerships. Ideally,
public funds may redirect part of their funding towards struc-
tural funding of longitudinal research initiatives, or the main-
tenance of longitudinal research initiatives may be
considered part of daily clinical practice and be reimbursed
as such.
Conclusions
The 3P initiative provides a comprehensive nationwide multi-
disciplinary research infrastructure to accommodate studies
on a national level and complement the paucity of popula-
tion-based data. Three nationwide comprehensive cohorts for
gastrointestinal cancer combine long-term clinical data, bio-
bank material (including tissue and blood), and PROs. These
are implemented using available best practices, internation-
ally accepted standards for data collection, and a broad
multi-step informed consent. Funding remains a challenge.
Data from this initiative are accessible for further (inter)-
national research that aims to improve health outcomes for
pancreatic, esophageal/gastric, and colorectal cancer patients.
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